article thumbnail

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

DAIC

mtaschetta-millane Wed, 07/10/2024 - 09:02 July 10, 2024 — CellProthera , a private company specializing in cell-based therapies for repairing ischemic tissues, and BioCardia, Inc. ,

article thumbnail

Association between waist-to-hip ratio and risk of myocardial infarction: a systematic evaluation and meta-analysis

Frontiers in Cardiovascular Medicine

Two researchers independently screened, extracted data, and assessed quality using the Newcastle-Ottawa Scale (NOS) and Revman5.3. Meta-analysis with Stata 16.0 calculated the combined Odd ratio (OR) for WHR and MI risk.

article thumbnail

No benefit of apoA-I infusion after myocardial infarction

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 03 May 2024; doi:10.1038/s41569-024-01031-z In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.

article thumbnail

Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction

The New England Journal of Medicine

A 69-year-old man with a history of MI and cardiomyopathy presented with 2 days of dyspnea. Regular tachycardia (124 beats per min), diaphoresis, and rales were present. A diagnosis was made.

article thumbnail

Case Report: Fatal atrioesophageal fistula following atrial fibrillation ablation—critical reflections on prevention

Frontiers in Cardiovascular Medicine

This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction. A 71-year-old male admitted to the emergency department on July 19, 2024, with acute loss of consciousness and convulsions.

article thumbnail

No Plaque, No Problem: Tackling Atherosclerosis Prevention

Cardiometabolic Health Congress

The Hidden Threat: SMuRFless Myocardial Infarctions A concerning trend in CVD is the increase in myocardial infarctions (MI) among individuals without standard modifiable risk factors (SMuRFless MI). Mortality is higher within 30 days of the event, as demonstrated in survival analyses from the SWEDEHEART registry.

article thumbnail

Results Involving Philips FDA-cleared AI-enabled Cardiovascular Ultrasound Platform to be Presented at American Society of Echocardiography Scientific Sessions, ASE 2024

DAIC

Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.